<DOC>
	<DOCNO>NCT00135356</DOCNO>
	<brief_summary>The purpose clinical research study learn human immunodeficiency virus ( HIV ) -infected subject abdominal fat accumulation highly active antiretroviral treatment ( HAART ) regimen good change fat distribution switch atazanavir-ritonavir remain current protease inhibitor boost HAART regimen .</brief_summary>
	<brief_title>Study Reyataz HIV-infected Patients With Lipodystrophy Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>HIV1 infect HAART regimen contain 2 NRTI boost PI least 12 week prior screen . Subjects may experience virological failure one prior PIcontaining regimen . Must able swallow tablet Viral load &lt; 400 c/mL screen stable least 6 month Signs fat redistribution lipohypertrophy ( abdominal ) Waist Hip Ratio &gt; 0.90 Waist Circumference &gt; 88.2 cm men Waist Circumference &gt; 75.3 woman Pregnant breastfeed woman New HIVrelated opportunistic infection Active alcohol substance use Grade 4 lab toxicity History take atazanavir ( ATV ) Prohibited therapy , include nonnucleoside reverse transcriptase inhibitor ( NNRTI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>HIV infection</keyword>
</DOC>